BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...

BioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...

Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...

The BioNTech SE ADR BNTX inched 0.69% higher to $113.05 Monday, on what proved to be an all-around positive trading session ...

While the new mRNA vaccines from Moderna and Pfizer-BioNTech have dominated the COVID-19 vaccine story, there is another type ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In July, a High Court judge delivered a mixed ruling in the long-running dispute that has pitted pharmaceutical giant Pfizer Inc and German drug manufacturer BioNTech SE, against Cambridge, ...

Discover BioNTech SE's innovative RNA lipoplex patent, detailing advanced methods for stable RNA delivery, GMP production, and effective intravenous administration.

BioNTech's shares have experienced a remarkable upswing, with the stock price soaring to $130.90 on NASDAQ, marking a 6.0% increase in the latest session. This surge represents a significant ...

Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently ...